close

Agreements

1 225 226 227 228 229 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2012-01-17 Complegen (USA) Boehringer Ingelheim (Germany) XenoGene™ Technology

licensing

Licensing agreement
2012-01-17 JPT Peptide Technologies GmbH (Germany) IUCT (Spain) LEITAT Technological Center (Spain) anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics cancer

R&D

Cancer - Oncology R&D agreement
2012-01-17 AC Immune (Switzerland) University of Basel (Switzerland) drugs for memory impairment memory impairment

collaboration
R&D

Neurodegenerative diseases - CNS diseases R&D agreement
2012-01-17 Scil Proteins (Germany) Actavis (Switzerland) Reteplase (Reteplase is a recombinant protein and the active ingredient in the medicinal product Rapilysin® for thrombolytic treatment of myocardial infarction) myocardial infarction

supply

Cardiovascular diseases Production agreement
2012-01-17 Redbiotec (Switzerland) DKFZ - German Cancer Research Center (Germany) chimeric VLPs (virus-like particles), containing proteins of different serotypes on one VLP. HPV (human papillomavirus) infections

R&D

Infectious diseases R&D agreement
2012-01-17 Almac (UK) MGB Biopharma (UK) MGB-BP3

production
manufacturing

Infectious diseases Production agreement
2012-01-13 Swedish Orphan Biovitrum SOBI (Sweden), Only for Children Pharmaceuticals (O4CP) (France) bumetanide diuresis and seizures in neonates

licensing

CNS diseases Licensing agreement
2012-01-12 Novalix (France) Teijin Pharma (Japan) novel drug candidates against multiple targets across different therapeutic areas undisclosed

R&D

undisclosed R&D agreement
2012-01-12 Covance USA) Inserm Transfert (France) Inserm Transfert Initiative (France) discovery and early development studies

collaboration
R&D

Collaboration agreement
2012-01-11 Octoplus (the Netherlands) undisclosed US-based pharmaceutical company (USA) controlled release formulation of the client's therapeutic compound for local delivery into joints

R

Collaboration agreement
2012-01-10 Qiagen (The Netherlands) Insight Genetics (USA) ALK (anaplastic lymphoma kinase) biomarker lung cancer

co-development
licensing

Cancer - Oncology Licensing agreement
2012-01-10 Qiagen (The Netherlands) Ipsogen (France) Personal Genome Diagnostics (USA) IDH1/IDH2 biomarker brain cancers, acute myelogenous leukemia (AML) and certain other malignancies Cancer Oncology Licensing agreement
2012-01-10 Dako (Denmark) Amgen (USA) diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer undisclosed cancer

development
collaboration

Cancer - Oncology Development agreement
2012-01-10 Ventana Medical Systems (USA - a member of Roche Group - Switzerland) Pfizer (USA - NY) Cell Signaling Technology (USA) immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer\'s XALKORI ® (crizotinib)

collaboration
licensing

Diagnostic - Cancer - Oncology Licensing agreement
2012-01-10 Sanofi (France) University of California, San Francisco (UCSF - USA) drug targets that could lead to new therapies for both type 1 and type 2 diabetes type 1 and type 2 diabetes

R&D

Metabolic diseases R&D agreement
2012-01-10 Sanofi (France) Foundation Medicine (USA) genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates cancer

R&D

Cancer Oncology Collaboration agreement
2012-01-09 Qiagen (The Netherlands) Max Planck Institute for Infection Biology (Germany) molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime tuberculosis Infectious diseases Development agreement
2012-01-09 NiKem Research (Italy) Dualsystems Biotech (Switzerland) drug/target profiling and drug discovery services

collaboration

Collaboration agreement
2012-01-09 KalVista Pharmaceuticals (UK) JDRF (USA) plasma kallikrein inhibitor diabetic macular edema R&D Metabolic diseases - Ophtalmological diseases
2012-01-09 Gentium (Italy) Swedish Orphan Biovitrum (Sweden) defibrotide prevention and treatment of hepatic veno-occlusive disease (VOD) distribution Digestive diseases